Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERENYSE:HIMSNASDAQ:ONEMNYSE:TDOC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERECerevel Therapeutics$44.96$43.67$19.59▼$44.99$8.19B1.41.71 million shsN/AHIMSHims & Hers Health$49.94+1.1%$50.57$13.47▼$72.98$11.06B2.0923.15 million shs36.43 million shsONEM1Life Healthcare$16.47$16.09$5.94▼$17.55$3.37B1.993.22 million shs523,503 shsTDOCTeladoc Health$8.73+3.8%$7.23$6.35▼$15.21$1.48B1.786.35 million shs7.89 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERECerevel Therapeutics0.00%0.00%0.00%0.00%+9.95%HIMSHims & Hers Health+1.04%+18.65%-11.98%+60.90%+147.35%ONEM1Life Healthcare0.00%0.00%0.00%0.00%0.00%TDOCTeladoc Health+3.60%+10.51%+26.16%+12.40%-10.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCERECerevel TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHIMSHims & Hers Health2.0843 of 5 stars2.02.00.00.01.73.31.9ONEM1Life HealthcareN/AN/AN/AN/AN/AN/AN/AN/ATDOCTeladoc Health2.0948 of 5 stars2.24.00.00.02.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCERECerevel Therapeutics 0.00N/AN/AN/AHIMSHims & Hers Health 1.92Reduce$39.58-20.74% DownsideONEM1Life Healthcare 0.00N/AN/AN/ATDOCTeladoc Health 2.37Hold$9.609.93% UpsideCurrent Analyst Ratings BreakdownLatest TDOC, ONEM, HIMS, and CERE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$45.006/23/2025HIMSHims & Hers HealthCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell6/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.006/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform6/23/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/11/2025HIMSHims & Hers HealthMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$40.006/4/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$61.00 ➝ $65.005/28/2025TDOCTeladoc HealthBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.005/27/2025TDOCTeladoc HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $9.005/8/2025TDOCTeladoc HealthWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.005/7/2025HIMSHims & Hers HealthDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCERECerevel TherapeuticsN/AN/AN/AN/A$3.71 per shareN/AHIMSHims & Hers Health$1.48B7.57$0.36 per share140.30$2.16 per share23.12ONEM1Life Healthcare$1.05B3.22N/AN/A$9.06 per share1.82TDOCTeladoc Health$2.57B0.60$5.78 per share1.51$8.66 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCERECerevel Therapeutics-$432.84M-$2.73N/AN/AN/AN/A-98.94%-45.07%N/AHIMSHims & Hers Health$126.04M$0.6972.3896.041.869.24%22.75%15.51%8/4/2025 (Estimated)ONEM1Life Healthcare-$254.64M-$2.01N/AN/AN/A-38.05%-24.58%-15.62%N/ATDOCTeladoc Health-$1.00B-$5.92N/AN/AN/A-39.66%-11.01%-4.66%7/30/2025 (Estimated)Latest TDOC, ONEM, HIMS, and CERE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025HIMSHims & Hers Health$0.12$0.20+$0.08$0.20$535.21 million$586.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCERECerevel TherapeuticsN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/AONEM1Life HealthcareN/AN/AN/AN/AN/ATDOCTeladoc HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCERECerevel Therapeutics0.6010.2210.22HIMSHims & Hers HealthN/A1.591.32ONEM1Life Healthcare0.202.092.06TDOCTeladoc Health0.701.681.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCERECerevel Therapeutics87.73%HIMSHims & Hers Health63.52%ONEM1Life Healthcare78.20%TDOCTeladoc Health76.82%Insider OwnershipCompanyInsider OwnershipCERECerevel Therapeutics5.10%HIMSHims & Hers Health17.71%ONEM1Life Healthcare4.40%TDOCTeladoc Health0.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCERECerevel Therapeutics300182.20 million172.90 millionOptionableHIMSHims & Hers Health1,637223.83 million184.19 millionOptionableONEM1Life Healthcare3,090204.35 million195.36 millionOptionableTDOCTeladoc Health5,500175.43 million174.42 millionOptionableTDOC, ONEM, HIMS, and CERE HeadlinesRecent News About These CompaniesBrokerages Set Teladoc Health, Inc. (NYSE:TDOC) Target Price at $9.60June 29 at 2:31 AM | americanbankingnews.comZacks Research Cuts Earnings Estimates for Teladoc HealthJune 27, 2025 | marketbeat.comTeladoc Health to Face Bulk of Pixel Tracking, Data Sharing SuitJune 26, 2025 | news.bloomberglaw.comNTeladoc Health, Inc. (NYSE:TDOC) Receives Average Recommendation of "Hold" from AnalystsJune 26, 2025 | marketbeat.comTeladoc Health (NYSE:TDOC) Stock Price Down 4.8% - What's Next?June 25, 2025 | marketbeat.comTeladoc Stock Is a ‘Coiled Spring’ That Could Surge Higher. Should You Buy TDOC Here?June 24, 2025 | msn.comTeladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?June 24, 2025 | zacks.comTeladoc Health (NYSE:TDOC) Sees Strong Trading Volume - Still a Buy?June 24, 2025 | marketbeat.comHere's why Teladoc Health stock price could surge 95%June 24, 2025 | invezz.comITraders Buy High Volume of Teladoc Health Call Options (NYSE:TDOC)June 24, 2025 | americanbankingnews.comTeladoc (TDOC) Stock Trades Up, Here Is WhyJune 23, 2025 | msn.comTeladoc Health (NYSE:TDOC) Shares Up 6.8% - What's Next?June 23, 2025 | marketbeat.comStock Traders Buy Large Volume of Teladoc Health Call Options (NYSE:TDOC)June 23, 2025 | marketbeat.comTeladoc (TDOC) Rises Higher Than Market: Key FactsJune 16, 2025 | zacks.comDivita lays out Teladoc's M&A strategy in CEO's 2nd yearJune 14, 2025 | fiercehealthcare.comFTeladoc Health, Inc. (TDOC) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)June 11, 2025 | seekingalpha.comTeladoc (TDOC) Outperforms Broader Market: What You Need to KnowJune 9, 2025 | zacks.comOmada Health: Helping Patients, Investors As Well?June 7, 2025 | seekingalpha.comTeladoc Health, Inc. (NYSE:TDOC) Shares Sold by Mackenzie Financial CorpJune 6, 2025 | marketbeat.comTeladoc Health to Participate in Upcoming Investor ConferenceJune 5, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 262,572 Shares of Teladoc Health, Inc. (NYSE:TDOC)June 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeHims & Hers Stock: Buy the Dip or Wait It Out?By Gabriel Osorio-Mazilli | June 5, 2025View Hims & Hers Stock: Buy the Dip or Wait It Out?Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingBy Gabriel Osorio-Mazilli | June 24, 2025View Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingTDOC, ONEM, HIMS, and CERE Company DescriptionsCerevel Therapeutics NASDAQ:CERECerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Hims & Hers Health NYSE:HIMS$49.94 +0.53 (+1.07%) As of 06/30/2025 03:58 PM EasternHims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.1Life Healthcare NASDAQ:ONEM1Life Healthcare, Inc. operates a membership-based primary care platform under the One Medical brand. The company has developed a healthcare membership model based on direct consumer enrollment, as well as third-party sponsorship. Its membership model includes seamless access to 24/7 digital health services paired with inviting in-office care routinely covered under health insurance programs. The company also offers administrative and managerial services pursuant to contracts with physician-owned professional corporations or One Medical Entities. As of December 31, 2021, it had 703,000 consumer and enterprise members, and 33,000 At-Risk members; 182 medical offices in 25 markets; and 8,500 enterprise clients in the United States. The company was incorporated in 2002 and is headquartered in San Francisco, California.Teladoc Health NYSE:TDOC$8.73 +0.32 (+3.80%) As of 06/30/2025 03:58 PM EasternTeladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
